

**GENOTYPING REPORT**

Patient Information	Routing Information	Account Information
Name/Initials: James Patrick/JPA	ResearchLab ID:	ADPM QA TEST
Patient ID: 112091990	Account Number:	ADPM QA DEPT Rtp.
SSN: 456-20-8456	Client ID:	RTP
Sex: Male	Collected: 03/04/2003	RTP
Birth Date: 12/3/74	Reported: 06/05/2004	MN12345-6789
Years Months		Phone: (456) 231-8900
Age: 29 / 4		Fax: (456) 231-8904
Visit:		Attn: Benjamin
		Delivery Route: 20 Mail Info: 9

Clinical Information X2345:3333333333, PA ;, WEIR000, C, T, R. 01/01/1980

Trade Name	Generic Name	Interpretation	Associated Mutations	Comments
------------	--------------	----------------	----------------------	----------

**NNRTI – Mutation Summary (190A)**

<b>S</b>	Rescriptor®	Delavirdine	<b>Sensitive</b>	190A	
<b>R</b>	Sustiva®	Efavirenz	<b>Resistant</b>	190A	
<b>R</b>	Viramune®	Nevirapine	<b>Resistant</b>	190A	

**NRTI – Mutation Summary (41L, 67N, 70R, 74I, 77L, 184V, 215F, 219Q)**

<b>R</b>	Hivid®	Zalcitabine	<b>Resistant</b>	184V, 215F, 219Q, 41L, 67N, 70R, 74I, 77L	
<b>R</b>	Epivir®	Lamivudine	<b>Resistant</b>	184V	
<b>R</b>	Retrovir®	Zidovudine	<b>Resistant</b>	184V, 215F, 219Q, 41L, 67N, 70R, 77L	Mutations at 184 can suppress the effects of ZDV associated mutations
<b>R</b>	Videx®	Didanosine	<b>Resistant</b>	184V, 215F, 219Q, 41L, 67N, 70R, 74I, 77L	
<b>R</b>	Zerit®	Stavudine	<b>Resistant</b>	184V, 215F, 219Q, 41L, 67N, 70R, 77L	Mutations at 184 can suppress the effects of ZDV associated mutations
<b>R</b>	Ziagen®	Abacavir	<b>Resistant</b>	184V, 215F, 219Q, 41L, 67N, 70R, 77L	
<b>RP</b>	Viread®	*Tenofovir (TDF)	<b>Resistance Possible</b>		Mutations at 184 can suppress the effects of ZDV associated mutations
<b>R</b>	Emtriva®	Emtricitabine	<b>Resistant</b>	184V	

**PI – Mutation Summary (77I)**

<b>S</b>	Agenerase®	Amprenavir	<b>Sensitive</b>		
<b>S</b>	Crixivan®	Indinavir	<b>Sensitive</b>	77I	
<b>S</b>	Invirase®/Fortovase®	Saquinavir	<b>Sensitive</b>	77I	
<b>S</b>	Norvir®	Ritonavir	<b>Sensitive</b>	77I	
<b>S</b>	Viracept®	Nelfinavir	<b>Sensitive</b>	77I	
<b>S</b>	Kaletra®	Lopinavir/r	<b>Sensitive</b>		
<b>S</b>	Rayataz®	Atazanavir	<b>Sensitive</b>		

**Legend:** **S** **RP** **R** [ ] Denotes Primary Mutation

A patient's response to therapy depends on multiple factors including the percentage of a patient's viral population that is resistant, drug pharmacokinetics, and medication compliance. Therefore, this test result should be interpreted in conjunction with the patient's antiretroviral treatment history, viral load count, and clinical status when making therapeutic decisions. This test may be unsuccessful if the plasma HIV RNA viral load is <1000 copies of virus per ml of plasma, measured with Roche Amplicor Monitor (Roche Diagnostic Systems, Branchburg NJ).

\*Expanded access, not currently FDA approved

**Molecular Biology and Pathology Center**

Lab Director  
Michael Montana

V.P. CMPBP  
Robert Hostler

Medical Director  
Gregg Kostmore